Investing

CellMosaic is currently raising funds to advance the synthesis and study of various AqT-linked drug modalities for future ADC partnerships and licensing. The company is also hiring key personnel to support the development and manufacturing of biocompatible AqT based bioconjugate research products for life science researchers. 

Our team is one of the most experienced in this industry, combining expertise from multiple fields to anticipate market trends and technological advances. This position helps us to develop groundbreaking, first-of-its-kind products and services. As the exclusive owner of patented AqT technology, we offer unique solutions that set us apart from competitors. 

We believe CellMosaic is on the verge of a major breakthrough with our AqT technology, which allows us to link hydrophobic molecules to biomolecules, opening up new possibilities for expanding innovative products for both scientific research and cancer treatment. 

Having personally seen friends, colleagues, and family members affected by cancer, we are deeply committed to helping cancer researchers and biopharmaceutical companies develop the next generation of ADCs using AqT technology. Our goal is to make ADC a first-line treatment, rather than a last resort, by addressing the harmful side effects that exist in current ADC therapies. ADCs are the future of a broader cancer treatment strategy due to their ability to deliver chemotherapeutics directly to the cancer cells. Creating an ADC with limited side effects is extremely difficult----CellMosaic’s AqT technology is the solution. 

Join us as we work to commercialize AqT technology, drive innovation, and ensure long-term success at CellMosaic. 

Sign Up to Receive Updates throughout Our Offering Period